Search

everythinglearnresearchcommunity

for

Search:↓

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

Pyrilutamide phase 3 results showed little to no significant hair regrowth, but may be sufficient for maintaining current hair density. The user is unsure due to lack of recent discussions on pyrilutamide.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

User considers trying RU58841 for hair loss and asks for advice on its effectiveness and application. Responses vary, with some reporting positive results and others warning about potential risks or lack of change.

A user's progress with treating hair loss over 3.5 months, which involves taking finasteride MWF, minoxidil daily and microneedling once a week. There was positive feedback from other users regarding the results.

A 30-year-old male has been experiencing hair loss despite using Dutasteride 0.5mg and PRP for 15 months, with no success. He is considering a hair transplant but is advised to stabilize hair loss first and explore other treatments like topical Minoxidil or combined therapies.

The user shared a 3-month update on using a 5% minoxidil and finasteride topical solution enriched with redensyl and procapil for hair regrowth. They mentioned inconsistency in using the treatment and initially starting it without consulting a dermatologist.

A user shared progress pictures after their fifth hair transplant, which included 3,000 grafts from both scalp and body hair. They use topical finasteride and minoxidil, and the procedure cost $22,000 at Maxim in Austin, Texas.

A 33-year-old female with androgenic alopecia experienced alopecia areata patches after PRP treatment. She is seeking others' experiences with PRP worsening alopecia areata.

A user has been using 1mg oral finasteride and 5% topical minoxidil for six months, with some derma stamping, but feels hair growth has stagnated and is considering PRP or a hair transplant. Others advise continuing the current regimen, noting that maintaining existing hair is an achievement, and suggest ignoring negative comments from friends.

A user started applying 25mg RU58841 daily for hair regrowth and is considering increasing the dosage. They are seeking advice on effective dosages from others who have experienced regrowth with RU58841.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

RU58841, combined with 5% minoxidil, helped reduce acne and hair loss. Users discussed using RU58841 cream for acne and shared experiences with other treatments like finasteride and dutasteride.

The user updated their hair loss treatment to include daily dutasteride, oral minoxidil, topical dutasteride with minoxidil and tretinoin, and RU58841. Commenters feel the extensive treatment is unnecessary for the user's level of hair loss.

The conversation is about finding affordable RU58841 for hair loss treatment. Suggestions include buying it in powder form and making a solution at home, with Amazon as a potential source.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.

Choosing between two hair loss treatments, with a preference for a higher concentration of RU58841 and 5% minoxidil, avoiding oils like castor and argan that may hinder absorption.

Using a combination of finasteride, minoxidil, dermarolling, and RU58841 to treat hair loss. Participants discussed the time commitment required for treatment and the effectiveness of different dosages.

RU58841 is discussed as a potential hair loss treatment. Minoxidil and finasteride are also mentioned as common treatments.

RU58841 is discussed as a hair loss treatment, with users considering lower doses like 2.5% to reduce costs. Some users suggest that if already blocking DHT, lower doses might still be effective unless there's high sensitivity to DHT.

The conversation humorously discusses the use of pp405 for hair loss, with mentions of finasteride and minoxidil. Users joke about unusual side effects like growing extra body parts.

The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.

PP405 targets hair follicle stem cells differently than exercise-induced lactate, suggesting exercise alone may not replicate its benefits. Minoxidil and finasteride are recommended alongside exercise for hair regrowth, with additional suggestions like spicy food and infrared exposure.

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.

ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

Lichen Planopilaris (LPP), a form of permanent hair loss, which can be mistaken for seborrheic dermatitis and is characterized by scalp itching, burning, redness, and dandruff. Treatment options discussed include steroidal creams, finasteride, minoxidil, and RU58841.